NGL Fine-Chem Limited

Price Chart

Risk-Adjusted Performance

NGL Fine-Chem Limited (NGLFINE) Price Performance

NGL Fine-Chem Limited (NGLFINE) trades on NSE in INR. The company is classified in the Healthcare sector under the Drug Manufacturers - General industry. The stock currently trades at INR2226.60, down 0.92% from the previous close.

Over the past year, NGLFINE has traded between a low of INR1202.87 and a high of INR2431.00. The stock has gained 81.4% over this period. It is currently 8.4% below its 52-week high.

NGL Fine-Chem Limited has a market capitalization of $14.02B, with a price-to-earnings ratio of 39.64.

About NGL Fine-Chem Limited

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, rafoxanide, diminazene aceturate, s-methoprene, carprofen, diminazene diaceturate, ractopamine HCI, toltrazuril, decoquinate, amitraz, marbofloxacin, flunixin meglumine, praziquantel, fenbendazole, and xylazine hydrochloride. It also provides human health pharmaceutical ingredients, including nitazoxanide and atovaquone; and intermediates and specialty chemicals comprising 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-ethyl glucamine. In addition, the company offers finished dosage forms, including diminazene aceturate granules and homidium chloride tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.

Compare NGL Fine-Chem Limited

Side-by-side comparison against top Healthcare peers.